Agios Stops Tebapivat in Sickle Cell Disease

Company Agios Pharmaceuticals Event Type Clinical Trial Results (Phase 2 — Program Discontinued) Modality Oral Pyruvate Kinase (PK) Activator Asset Tebapivat Target Red-Cell Pyruvate Kinase (PKLR) Disease Area Sickle Cell Disease Summary Agios will not advance tebapivat in sickle cell disease after a 59-patient Phase…